Fighting Post-COVID and ME/CFS – development of curative therapies
暂无分享,去创建一个
F. Knolle | C. Meisel | C. Scheibenbogen | J. Bellmann-Strobl | F. Konietschke | D. Hedderich | M. Ralser | J. Schultze | H. Audebert | L. Bruckert | U. Behrends | A. Aschenbrenner | H. Prüss | M. Vehreschild | B. Sawitzki | M. Mülleder | L. Sander | C. Franke | H. Zimmermann | S. Burock | A. Krueger | M. Toelle | S. Stojanov | K. Wittke | Carsten Finke | H. Pressler | Friedemann Paul | Marie-Luise Machule | Gabriela Riemekasten | E. Stein | Marc Beyer | O. Cornely | Cornelia Heindrich | Marc D. Beyer | G. Riemekasten | C. Finke | Anne Krueger | C. Heindrich | Kirsten Wittke | Carsten Finke
[1] C. Scheibenbogen,et al. Structural brain changes in patients with post-COVID fatigue: a prospective observational study , 2023, eClinicalMedicine.
[2] Ø. Fluge,et al. Endothelial dysfunction in ME/CFS patients , 2023, PloS one.
[3] M. Leitzke. Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration? , 2023, Bioelectronic Medicine.
[4] E. Topol,et al. Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.
[5] J. Verschuuren,et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) , 2023, Journal of Neurology.
[6] H. Audebert,et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome , 2023, Brain, Behavior, and Immunity.
[7] David M. Liebovitz,et al. Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up , 2022, medRxiv.
[8] A. Arnsten,et al. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19” , 2022, Neuroimmunology Reports.
[9] L. Wieler,et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany , 2022, PLoS medicine.
[10] T. Harrer,et al. Post-COVID-19 Syndrome: Retinal Microcirculation as a Potential Marker for Chronic Fatigue , 2022, medRxiv.
[11] Quanzhen Li,et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms , 2022, European Respiratory Journal.
[12] H. Makhlouf,et al. Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study , 2022, The Egyptian Journal of Bronchology.
[13] H. Volk,et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity , 2022, Nature Communications.
[14] R. Shafer,et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic. , 2022, medRxiv.
[15] J. Rosmalen,et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study , 2022, The Lancet.
[16] Heidi Ledford. Long-COVID treatments: why the world is still waiting , 2022, Nature.
[17] G. Gkoutos,et al. Symptoms and risk factors for long COVID in non-hospitalized adults , 2022, Nature Medicine.
[18] S. Efrati,et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial , 2022, Scientific Reports.
[19] J. Lambert,et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study , 2022, Brain, Behavior, & Immunity - Health.
[20] S. Hippenstiel,et al. A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study , 2022, eClinicalMedicine.
[21] Z. Al-Aly,et al. Long COVID after breakthrough SARS-CoV-2 infection , 2022, Nature Medicine.
[22] A. Waickman,et al. Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infection , 2022, Current Opinion in Immunology.
[23] A. Iwasaki,et al. Unexplained post-acute infection syndromes , 2022, Nature Medicine.
[24] W. Xiao,et al. Neurovascular Dysregulation and Acute Exercise Intolerance in ME/CFS: A Randomized, Placebo-Controlled Trial of Pyridostigmine. , 2022, Chest.
[25] P. Ravaud,et al. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort , 2022, Nature Communications.
[26] F. Paul,et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) , 2022, Journal of translational medicine.
[27] M. Puhan,et al. Long COVID Through a Public Health Lens: An Umbrella Review , 2022, Public Health Reviews.
[28] K. C. Morris,et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis , 2022, medRxiv.
[29] Lennart M. Reinke,et al. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics , 2022, European Journal of Epidemiology.
[30] F. Binkofski,et al. Long COVID‐19: Objectifying most self‐reported neurological symptoms , 2022, Annals of clinical and translational neurology.
[31] M. Povero,et al. Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study , 2022, Multidisciplinary respiratory medicine.
[32] Inyoul Y. Lee,et al. Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.
[33] R. Shafran,et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies , 2021, Journal of Infection.
[34] E. Paz-Artal,et al. A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID , 2021, Biomedicines.
[35] R. Viner,et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies , 2021, Journal of Infection.
[36] J. Rip,et al. Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease , 2021, Drugs.
[37] Ø. Fluge,et al. Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). , 2021, The Journal of clinical investigation.
[38] V. Gant,et al. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines , 2021, medRxiv.
[39] C. Scheibenbogen,et al. European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe , 2021, Medicina.
[40] F. Paul,et al. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder. , 2021, Drugs of today.
[41] K. Miwa. Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage , 2021, Internal medicine.
[42] C. Scheibenbogen,et al. Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS , 2021, Journal of translational medicine.
[43] T. Yamamura,et al. Skewing of the B cell receptor repertoire in myalgic encephalomyelitis/chronic fatigue syndrome , 2021, Brain, Behavior, and Immunity.
[44] Hong C Shen,et al. Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): kinase inhibitors. , 2021, Bioorganic & medicinal chemistry letters.
[45] A. Subramanian,et al. Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole , 2021, Journal of translational medicine.
[46] J. Ballon,et al. Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole , 2021, Journal of Translational Medicine.
[47] D. Strayer,et al. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2020, PloS one.
[48] K. Anstrom,et al. Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. , 2020, New England Journal of Medicine.
[49] B. Maron,et al. Vericiguat in Heart Failure with Reduced Ejection Fraction. , 2020, New England Journal of Medicine.
[50] I. Brandslund,et al. EUROPEAN ME NETWORK (EUROMENE) Expert Consensus on the Diagnosis, Service Provision and Care of People with ME/CFS in Europe , 2020 .
[51] Alexander Sczyrba,et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment , 2020, Cell.
[52] Christoph B. Messner,et al. Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection , 2020, Cell Systems.
[53] C. Scheibenbogen,et al. Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset , 2020, Frontiers in Immunology.
[54] G. Wallukat,et al. A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects , 2020, Clinical Drug Investigation.
[55] O. Polo,et al. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) , 2019, Fatigue: Biomedicine, Health & Behavior.
[56] I. Brandslund,et al. [Myalgic encephalomyelitis or chronic fatigue syndrome]. , 2019, Ugeskrift for laeger.
[57] O. Bruland,et al. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2019, Annals of Internal Medicine.
[58] M. VanElzakker,et al. Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods , 2019, Front. Neurol..
[59] Mark M. Davis,et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients , 2017, Proceedings of the National Academy of Sciences.
[60] D. Blockmans,et al. Long-term methylphenidate intake in chronic fatigue syndrome , 2016, Acta clinica Belgica.
[61] Ø. Fluge,et al. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment , 2015, PloS one.
[62] Mady Hornig,et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness , 2015, Science Advances.
[63] Joel L. Young. Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled study , 2013, Psychiatry Research.
[64] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[65] J. Corner. Assessment of nurses' attitudes towards cancer: a critical review of research methods. , 1988, Journal of advanced nursing.
[66] Katz. Risks for Developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in College Students Following Infectious Mononucleosis: A Prospective Cohort Study , 2021 .
[67] J. Routy,et al. Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.
[68] D. Ilstrup,et al. A Double-blind, Placebo-Controlled Study , 2017 .
[69] Marta Elena Losa-Iglesias,et al. Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.
[70] B. Kuster,et al. Kinase Inhibitors , 2012, Methods in Molecular Biology.
[71] V. Preedy,et al. Prospective Cohort Study , 2010 .
[72] Thomas R. Riley,et al. A Randomized Double-blind Placebo-controlled Trial , 2004 .